Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press43110.36691/RJA431ArticlesСтатьиResearch ArticleModern approaches to specific immunotherapy in atopic dermatitis childrenСовременные подходы к специфической иммунотерапии детей с атопическим дерматитомSlavyanskayaT AСлавянскаяТ Аtslavyanskaya@gmail.comDerkachV VДеркачВ ВSepiashviliR IСепиашвилиР ИPeople's Friendship University of RussiaРоссийский университет дружбы народовInstitute of ImmunophysiologyИнститут иммунофизиологииPacific State Medical UniversityТихоокеанский государственный медицинский университет15102015125NO5 (2015)№5 (2015)313810032020Copyright ©; 2015, Pharmarus Print MediaCopyright ©; 2015, Фармарус Принт Медиа2015Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/431

This review presents the results of scientific research studies, systematical and metaanalyses data which confirm clinical efficiency of allergen specific immunotherapy (ASIT) in atopic dermatitis (AD) children. This review shows prospects for the use of combined immunotherapy, including ASIT and immunomodulators.

В обзоре представлены результаты научных исследований, системных и мета-анализов, подтверждающих клиническую эффективность аллерген-специфической иммунотерапии (АСИТ) при атопическом дерматите (АтД) у детей. Проанализированы современные достижения в области изучения АСИТ, показана перспектива использования комбинированной иммунотерапии, указаны неудовлетворенные потребности. Включение АСИТ является обоснованным только при аллергической форме АтД. Показана перспектива использования комбинированной иммунотерапии, сочетающей АСИТ и иммуномодулирующие препараты. Накопление клинического опыта с проведением рандомизированных исследований и разработка руководящих принципов АСИТ для детей с АтД являются необходимыми.

allergenspecific immunotherapysubcutaneous /sublingual immunotherapyatopic dermatitistreatmentаллергенспецифическая иммунотерапияподкожная/сублингвальная иммунотерапияатопический дерматитстратегия леченияDe Benedetto A., Rafaels N.M., McGirt L.Y. et al. Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2011, v. 127, p. 773-786.Jutel M., Van de Veen W., Agache I. et al. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol. Int. 2013, v. 62, p. 425-433.Sprecher E., Leung D.Y. Atopic dermatitis: scratching through the complexity of barrier dysfunction. J. Allergy Clin. Immunol. 2013, v. 132, p. 1130-1131.Сепиашвили Р.И., Мачарадзе Д.Ш., Славянская Т.А., Сепиашвили Я.Р. Этиология и факторы риска развития атопического дерматита. Аллергология и иммунология. 2008, № 2, с. 205-208.Славянская Т.А., Сепиашвили Р.И. Роль цитокинов в иммунопатологии. Аллергология и иммунология. 2004, № 1, с. 42.Odhiambo J.A., Williams H.C., Clayton T.O. et al. ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J. Allergy Clin. Immunol. 2009, v. 124, p. 1251-1258.Peters A.S., Kellberger J., Vogelberg C. et al. Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study. J. Allergy Clin. Immunol. 2010, v. 126, p. 590-595.Shaw T.E., Currie G.P., Koudelka C.W., Simpson E.L. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J. Invest Dermatol. 2011, v. 131, p. 67-73.Stensen L., Thomsen S.F., Backer V. Change in prevalence of atopic dermatitis between 1986 and 2001 among children. Allergy Asthma Proc. 2008, v. 29, p. 392-396.Сепиашвили Р.И., Мачарадзе Д.Ш., Славянская Т.А., Тарасова С.В. Распространенность симптомов астмы и атопии среди детей СВАО г. Москвы по критериям ISAAC и объективным данным. International Journal on Immunorehabilitation. 1998, № 10, с. 168-173.Boguniewicz M., Leung D.Y. Recent insights into atopic dermatitis and implications for management of infectious complications. J. Allergy Clin. Immunol. 2010, v. 125, p. 4-13.Славянская Т.А., Деркач В.В. Тяжелые формы атопического дерматита у детей: как избежать осложнений? Вестн. последиплом. мед. образования. 2014, № 4, с. 47-48.Славянская Т.А., Деркач В.В., Сангидорж Б. Атопический дерматит у детей: комбинированная иммунотерапия осложненных форм заболевания. Рос^ иммунол. журн. 2014, № 3, с. 727-729.Славянская Т.А., Деркач В.В. Современные подходы к управлению среднетяжелым и тяжелым атопическим дерматитом у детей. Аллергология и иммунология. 2015, № 2, 219 с.Avgerinou G. Atopic dermatitis: new immunologic aspects. Int. J. Dermatol. 2008, v. 47, p. 219-224.Hata T.R., Gallo R. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin. Cutan. Med. Surg. 2008, v. 27, p. 144-150.М.С. Тренева, А.Н. Пампура. Антимикробные пептиды в патогенезе атопического дерматита. Росс. вестн. перинатологии и педиатрии. 2011, № 2, с. 80-84.Zhang E., Tanaka T., Tajima M. et al. Characterization of the skin fungal microbiota in patients with atopic dermatitis and in healthy subjects. Microbiol. Immunol. 2011, v. 55, p. 625-632.Деркач В.В., Славянская Т.А. Атопический дерматит у детей: особенности терапии и качество жизни. Вест. нац. медико-хирург. центра им. Н.И. Пирогова. 2013, № 3, с. 86-88.Derkach V., Slavyanskaya Т. Severe atopic dermatitis and quality of life in children during background therapy. J. Allergy Clin. Immunol. 2013 Suppl., v. 131, р. 129.Bouton C., Ducommun J. Specific immunotherapy design questions. Rev. Med. Suisse. 2009, v. 5, p. 832-836.Bussmann C., Böckenhoff A., Henke H. et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J. Allergy Clin. Immunol. 2006, v. 118, p. 1292-1298.Darsow U. Allergen-specific immunotherapy for atopic eczema: updated. Curr. Opin. Allergy Clin. Immunol. 2012, v. 12, p. 665-669.Nankervis H., Pynn E.V., Boyle R.J. et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst. Rev. 2015, 8426 p.Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2007, v. 7, p. 542-546.Elisyutina O., Fedenko E. Specific immunotherapy in atopic dermatitis with staphylococcal and house dust mite allergovaccines. Allergy. 2007, v. 62, р. 92.Елисютина О.Г., Феденко Е.С. Место специфической иммунотерапии в лечении больных атопическим дерматитом, осложненным рецидивирующей пиодермией. Физиология и патология иммунной системы. 2006, № 8, с. 15-20.Аллергология. Федеральные клинические рекомендации под ред. Р.М. Хаитова и Н.И. Ильиной. М., «Фармарус Принт Медиа». 2014, 86 с.Kaufman H.S., Roth H.L. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann. Allergy. 1974, v. 32, p. 321-330.Warner J.O., Price J.F., Soothill J.F., Hey E.N. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978, v. 2, p. 912-915.Glover M.T., Atherton D.J. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin. Exp. Allergy. 1992, v. 22, p. 440-446.Werfel T., Zuberbier T. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology. American Academy of Allergy, Asthma and Immunology. PRACTALL Consensus Report. Allergy. 2006, v. 61, p. 969-987.Silny W., Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis-results of double blind placebo controlled study. Pol. Merkur. Lekarski. 2006, v. 21, p. 558-565.Silny W., Czarnecka-Operacz M., Silny P. Effectiveness of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. Serum concentrations of selected immunologic parameters. Wiad. Lek. 2005, v. 58, p. 287-294.Silny W., Czarnecka-Operacz M., Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis Part II. Evaluation of skin reactivity and concentration of serum antigen specific immunoglobulin E directed against selected airborne allergens. Wiad. Lek. 2005, v. 58, p. 184-192.Silny W., Czarnecka-Operacz M., Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiad. Lek. 2005, v. 58, p. 47-55.Bussmann C., Maintz L., Hart J. et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin. Exp. Allergy. 2007, v. 37, p. 1277-1285.Czarnecka-Operacz M., Silny W. Specific immunotherapy in atopic dermatitis-Four-year treatment in different age and airborne allergy type subgroups. Acta Dermatovenerol. Croat. 2006, v. 14, No. 4, p. 230-240.Nahm D.H., Lee E.S., Park H.J. et al. Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex. Int. Arch. Allergy Immunol. 2008, v. 146, p. 235-240.Nankervis H., Pynn E.V., Boyle R.J. et al. Subcutaneous injection immunotherapy for optimal effectiveness. Immunol. Allergy Clin. North Am. 2011, v. 31, p. 211-226.Novak N., Thaci D., Hoffmann M. et al. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract-a new therapeutic option for patients with atopic dermatitis. Int. Arch Allergy Immunol. 2011, v. 155, p. 252-256.Sânchez-Machin I. Case report: specific immunotherapy with dust mite allergens in a child with severe atopic dermatitis. Allergol. Immunopathol. (Madr.). 2011, v. 39, p. 310-311.Burks A.W., Calderon M.A., Casale T. et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology. European Academy of Allergy & Clinical Immunology. PRACTALL consensus report. J. Allergy Clin. Immunol. 2013, v. 131, p. 1288-1296.Canonica G.W., Cox L., Pawankar R. et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014, v. 7, 6 p.Compalati E., Braido F., Canonica G.W. Sublingual immunotherapy: recent advances. Allergol. Int. 2013, v. 62, p. 415-423.Cox L., Compalati E., Kundig T., Larche M. New directions in immunotherapy. Curr. Allergy Asthma Rep. 2013, v. 13, p. 178-195.Compalati E., Passalacqua G., Bonini M., Canonica G.W. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009, v. 64, p. 1570-1579.Passalacqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organ J. 2014, v. 7, 21 p.Jutel M., Agache I., Bonini S. et al. International consensus on allergy immunotherapy. Position paper. J. Allergy Clin. Immunol. 2015 (article in press).Frati F., Ridolo E., Fuiano N. et al. Safety of sublingual immunotherapy in children. Expert Opin. Drug. Saf. 2014, v. 13, p. 947-953.Galli E., Chini L., Nardi S. et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol. Immunopathol. (Madr.). 1994, v. 22, p. 18-22.Pajno G.B., Caminiti L., Vita D. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 2007, v. 120, p. 164-170.Cadario G., Galluccio A.G., Pezza M. et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr. Med. Res. Opin. 2007, v. 23, p. 2503-2506.Larenas-Linnemann D. Certainties and doubts about sublingual and oral immunotherapy in children. Curr. Opin. Allergy Clin. Immunol. 2009, v. 9, p. 558-567.Bae J.M., Choi Y.Y., Park C.O. et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J. Allergy Clin. Immunol. 2013, v. 132, p. 110-117.Pleskovic N., Bartholow A., Skoner D.P Sublingual immunotherapy in children: the recent experiences. Curr. Opin. Allergy Clin. Immunol. 2014, v. 14, p. 582-590.Di Rienzo V., Cadario G., Grieco T. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Ann. Allergy Asthma Immunol. 2014, v. 113, p. 671-673.Arkwright P.D., Stafford J.C., Sharma V. Atopic dermatitis in children. J. Allergy Clin. Immunol. Pract. 2014, v. 2, p. 388-395.Choi J.S., Ryu H.R., Yoon C.H. Treatment of patients with refractory atopic dermatitis sensitized to house dust mites by using sublingual allergen immunotherapy. Ann. Dermatol. 2015, v. 27, p. 82-86.Pasalaqua G. Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organization J. 2014, v. 7, 21p. http://www.waojournal.org/content/771/21.Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organization J. 2015, v. 8, p. 17.Akkoc T., Akdis M., Akdis C.A. Update in the mechanisms of allergen-specific immunotherapy. Allergy Asthma Immunol. Res. 2011, v. 3, p. 11-20.Akdis C.A. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat. Med. 2012, v. 18, p. 736-749.Compalati E., Rogkakou A., Passalacqua G., Canonica G.W. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr. Opin. Allergy Clin. Immunol. 2012, v. 12, p. 427-433.Kopp M.V., Brauburger J., Riedinger F. et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 2002, v. 110, p. 728-735.Kopp M.V. Role of immunomodulators in allergen-specific immunotherapy. Allergy. 2011, v. 66, p. 792-797.Parks K.W., Casale T.B. Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Allergy Asthma Proc. 2006, v. 27, p. S33-36.Stock P., Rolinck-Werninghaus C., Wahn U., Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs. 2007, v. 21, p. 403-410.Barrios L.J., Bégin. P., Paradis L. et al. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J. Am. Acad. Dermatol. 2013, v. 69, р. 832-834.Sánchez-Ramón S., Eguíluz-Gracia I., Rodríguez-Mazariego M.E. et al. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J. Investig. Allergol. Clin. Immunol. 2013, v. 23, p. 190-196.Zink A., Gensbaur A., Zirbs M. et al. Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab. Acta Derm. Vfenereol. 2015, doi: 10.2340/00015555-2165.Mastrandrea F. The potential role of allergen-specific sublingual immunotherapy in atopic dermatitis. Am. J. Clin. Dermatol. 2004, v. 5, p. 281-294.Harskamp C.T., Armstrong A.W. Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies. Semin. Cutan. Med. Surg. 2013, v. 32, p. 132-139.Paller A.S. Latest approaches to treating atopic dermatitis. Chem. Immunol. Allergy. 2012, v. 96, p. 132-140.Novak N., Simon D. Atopic dermatitis - from new pathophysiologic insights to individualized therapy. Allergy. 2011, v. 66, p. 830-839.Derkach V., Slavyanskaya T. Combined immunotherapy in children with atopic dermatitis: rationale for application. Allergy. Asthma & Immunophysiology: from Genes to Clinical Management. Ed. R. Sepiashvili. MeDiMOND Int. Proc. 2014, p. 63-67.Derkach V., Slavyanskaya T. Comparative analysis of pharmacoeffectiveness of various programs of immunotropic therapy of children with atopic dermatitis. Allergy, Asthma & Immunophysiology: from basic sciences to clinical management. Ed. R. Sepiashvili. MEDIMOND Int. Proc. 2013, p. 43-45.Derkach V., Slavyanskaya Т. Comparative characteristic of effectiveness of immunotherapy of children with atopic dermatitis. Allergy, Asthma & Immunophysiology: Recent Advances in understanding and Management. Ed. R. Sepiashvili. MEDIMOND Int. Proc. 2015, p. 45-49.Derkach V., Slavyanskaya Т. Effectiveness of immunotherapy in children with atopic dermatitis. Int. J. on Immunorehabilitation. 2015, v. 17, p. 9-12.Slavyanskaya T., Derkach V., Sangidorj B. Atopic dermatitis in children: cost-effectiveness comparative estimation of various immunotropic therapy programmes. Ann. Allergy, Asthma & Immunology. 2014, v. 113, p. A113.Slavyanskaya T., Derkach V. Allergen-specific immunotherapy, as a pathogenetically justified method of treatment of children with atopic dermatitis. Allergy, Asthma & Immunophysiology: from basic sciences to clinical management». Ed. R. Sepiashvili. MEDIMOND Int. Proc. 2013, p. 39-41.Derkach V., Slavyanskaya T. Cost-effectiveness of immunotropic therapy for children with atopic dermatitis. World Allergy Organization J. 2013, v. 6, 228 р. 8 3. Slavyanskaya T., Derkach V. Clinical and immunologic characteristics of allergen-specific immunotherapy in children with atopic dermatitis. Wrrld Allergy Organization J. 2013, v. 6, p. 94.Lee J., Park C.O., Lee K.H. Specific immunotherapy in atopic dermatitis. Allergy Asthma Immunol Res. 2015, v. 7, p. 221-229.Calderon M.A., Gerth van Wijk R., Eichler I. et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr. Allergy Immunol. 2012, v. 23, p. 300-306.Mastrandrea F., Serio G., Minelli M. et al. Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol. Immunopathol. (Madr.) 2000, v. 28, p. 54-62.